FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201026130> ?p ?o ?g. }

• W3201026130 endingPage "730" @default.
• W3201026130 startingPage "717" @default.
• W3201026130 abstract "Abstract Single antigen–targeted chimeric antigen receptor (CAR) T-cell therapy may be insufficient to induce a durable response in pediatric aggressive B-cell lymphomas. This clinical trial examined the feasibility of sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric relapsed/refractory (R/R) Burkitt lymphoma. Twenty-three patients received the first CD19 CAR T-cell infusion. The patients who did not achieve an ongoing complete response (CR) underwent 1 or more sequential infusions of CAR T-cell therapy that targeted CD22 followed by CD20 according to their disease status and CAR T-cell persistence after each infusion. The median time from the last infusion to the cutoff date was 17 months (range, 15-23 months). The estimated 18-month CR rate was 78% (95% confidence interval [CI], 54%-91%). The estimated 18-month progression-free survival rate was 78% (95% CI, 55%-90%), with 78% (95% CI, 37%-94%) in patients with bulky disease and 60% (95% CI, 25%-83%) in patients with central nervous system (CNS) involvement. During the first CD19 CAR T-cell infusion, grade ≥3 cytokine release syndrome (CRS) occurred in 34.8% and neurotoxicity occurred in 21.7% of all patients. During subsequent infusions, there were only a few incidences of grade &gt;2 CRS and neurotoxicity. All adverse events were reversible. The severity of neurotoxicity was not significantly different between patients with CNS involvement and those who did not have CNS involvement. Sequential CAR T-cell therapy may result in a durable response and is safe in pediatric R/R Burkitt lymphoma. Patients with CNS involvement may benefit from sequential CAR T-cell therapy. This trial was registered at www.chictr.org.cn/index.aspx as #ChiCTR1800014457." @default.
• W3201026130 created "2021-09-27" @default.
• W3201026130 creator A5015467515 @default.
• W3201026130 creator A5023363049 @default.
• W3201026130 creator A5027349510 @default.
• W3201026130 creator A5031293399 @default.
• W3201026130 creator A5034190677 @default.
• W3201026130 creator A5038297770 @default.
• W3201026130 creator A5044622075 @default.
• W3201026130 creator A5046736252 @default.
• W3201026130 creator A5047802977 @default.
• W3201026130 creator A5050919158 @default.
• W3201026130 creator A5058568961 @default.
• W3201026130 creator A5059346751 @default.
• W3201026130 creator A5060002817 @default.
• W3201026130 creator A5060842906 @default.
• W3201026130 creator A5067347223 @default.
• W3201026130 creator A5068947466 @default.
• W3201026130 creator A5073737867 @default.
• W3201026130 creator A5083780461 @default.
• W3201026130 creator A5084358791 @default.
• W3201026130 creator A5086140764 @default.
• W3201026130 date "2022-01-27" @default.
• W3201026130 modified "2023-10-16" @default.
• W3201026130 title "Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma" @default.
• W3201026130 cites W1974184061 @default.
• W3201026130 cites W1998851035 @default.
• W3201026130 cites W1999777558 @default.
• W3201026130 cites W2000871066 @default.
• W3201026130 cites W2045940197 @default.
• W3201026130 cites W2077362224 @default.
• W3201026130 cites W2111914092 @default.
• W3201026130 cites W2118796952 @default.
• W3201026130 cites W2134766521 @default.
• W3201026130 cites W2139539910 @default.
• W3201026130 cites W2144594787 @default.
• W3201026130 cites W2156073127 @default.
• W3201026130 cites W2159263318 @default.
• W3201026130 cites W2179454156 @default.
• W3201026130 cites W2338495337 @default.
• W3201026130 cites W2343596911 @default.
• W3201026130 cites W2613659662 @default.
• W3201026130 cites W2773804840 @default.
• W3201026130 cites W2775369717 @default.
• W3201026130 cites W2788841996 @default.
• W3201026130 cites W2810990597 @default.
• W3201026130 cites W2878403994 @default.
• W3201026130 cites W2883693386 @default.
• W3201026130 cites W2887725799 @default.
• W3201026130 cites W2899173439 @default.
• W3201026130 cites W2899700403 @default.
• W3201026130 cites W2903062212 @default.
• W3201026130 cites W2903225254 @default.
• W3201026130 cites W2905654445 @default.
• W3201026130 cites W2922798588 @default.
• W3201026130 cites W2937806960 @default.
• W3201026130 cites W2946567117 @default.
• W3201026130 cites W2982859960 @default.
• W3201026130 cites W2990377810 @default.
• W3201026130 cites W3001173747 @default.
• W3201026130 cites W3016426931 @default.
• W3201026130 cites W3028983520 @default.
• W3201026130 cites W3031891765 @default.
• W3201026130 cites W3036279197 @default.
• W3201026130 cites W3047524085 @default.
• W3201026130 cites W3082855561 @default.
• W3201026130 cites W3110237706 @default.
• W3201026130 cites W3128956257 @default.
• W3201026130 doi "https://doi.org/10.1182/bloodadvances.2021004557" @default.
• W3201026130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34521107" @default.
• W3201026130 hasPublicationYear "2022" @default.
• W3201026130 type Work @default.
• W3201026130 sameAs 3201026130 @default.
• W3201026130 citedByCount "14" @default.
• W3201026130 countsByYear W32010261302022 @default.
• W3201026130 countsByYear W32010261302023 @default.
• W3201026130 crossrefType "journal-article" @default.
• W3201026130 hasAuthorship W3201026130A5015467515 @default.
• W3201026130 hasAuthorship W3201026130A5023363049 @default.
• W3201026130 hasAuthorship W3201026130A5027349510 @default.
• W3201026130 hasAuthorship W3201026130A5031293399 @default.
• W3201026130 hasAuthorship W3201026130A5034190677 @default.
• W3201026130 hasAuthorship W3201026130A5038297770 @default.
• W3201026130 hasAuthorship W3201026130A5044622075 @default.
• W3201026130 hasAuthorship W3201026130A5046736252 @default.
• W3201026130 hasAuthorship W3201026130A5047802977 @default.
• W3201026130 hasAuthorship W3201026130A5050919158 @default.
• W3201026130 hasAuthorship W3201026130A5058568961 @default.
• W3201026130 hasAuthorship W3201026130A5059346751 @default.
• W3201026130 hasAuthorship W3201026130A5060002817 @default.
• W3201026130 hasAuthorship W3201026130A5060842906 @default.
• W3201026130 hasAuthorship W3201026130A5067347223 @default.
• W3201026130 hasAuthorship W3201026130A5068947466 @default.
• W3201026130 hasAuthorship W3201026130A5073737867 @default.
• W3201026130 hasAuthorship W3201026130A5083780461 @default.
• W3201026130 hasAuthorship W3201026130A5084358791 @default.
• W3201026130 hasAuthorship W3201026130A5086140764 @default.
• W3201026130 hasBestOaLocation W32010261301 @default.

• next